Revelation Biosciences, Inc.
REVB
$3.08
$0.082.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 965.70K | 1.13M | 1.18M | 1.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.75M | 1.80M | 2.52M | 1.90M | 2.33M |
| Operating Income | -1.75M | -1.80M | -2.52M | -1.90M | -2.33M |
| Income Before Tax | -1.73M | -2.24M | -8.39M | -2.68M | -2.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.73M | -2.24M | -8.39M | -2.68M | -2.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.73M | -2.24M | -8.39M | -2.68M | -2.20M |
| EBIT | -1.75M | -1.80M | -2.52M | -1.90M | -2.33M |
| EBITDA | -1.75M | -1.79M | -2.52M | -1.90M | -2.32M |
| EPS Basic | -4.98 | -13.38 | -82.09 | -39.37 | -133.23 |
| Normalized Basic EPS | -3.11 | -8.36 | -51.31 | -24.60 | -83.27 |
| EPS Diluted | -4.98 | -13.44 | -82.09 | -39.37 | -133.28 |
| Normalized Diluted EPS | -3.11 | -8.36 | -51.31 | -24.60 | -83.27 |
| Average Basic Shares Outstanding | 346.50K | 167.50K | 102.20K | 68.10K | 16.50K |
| Average Diluted Shares Outstanding | 346.50K | 167.50K | 102.20K | 68.10K | 16.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |